natgillin/translations-raw huggingface dataset:
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 and 56 x 1 film-coated tablet in unit dose blisters and pack size of 28 fim-coated tablets in non-perforated calendar blisters.
Zdravilo Irbesartan Teva je na voljo v pakiranjih po 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 in 100 filmsko obloženih tablet v pretisnih omotih; velikosti pakiranj po 50 x 1 in 56 x 1 filmsko obložena tableta v pretisnih omotih za enkratno odmerjanje in velikost pakiranja po 28 filmsko obloženih tablet v koledarskem pretisnem omotu.
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizies of 50 x 1 and 56 x 1 film-coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters..
Zdravilo Irbesartan Teva je na voljo v pakiranjih po 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 in 100 filmsko obloženih tablet v pretisnih omotih; velikosti pakiranj po 50 x 1 in 56 x 1 filmsko obložena tableta v pretisnih omotih za enkratno odmerjanje in velikost pakiranja po 28 filmsko obloženih tablet v koledarskem pretisnem omotu.
Irbesartan Teva is for oral use.
Zdravilo Irbesartan Teva je potrebno zaužiti.
Irbesartan Teva is indicated in adults for the treatment of essential hypertension.
Zdravilo Irbesartan Teva je indicirano za zdravljenje esencialne hipertenzije.
Irbesartan Teva is used in adult patients
Irbesartan Teva uporabljamo pri odraslih bolnikih:
Irbesartan Teva slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 zdravilo Irbesartan Teva upočasni pešanje delovanja ledvic.
Irbesartan Zentiva 150 mg film-coated tablets.
Irbesartan Zentiva 150 mg filmsko obložene tablete.
Irbesartan Zentiva 300 mg film-coated tablets.
Irbesartan Zentiva 300 mg filmsko obložene tablete.
Irbesartan Zentiva 75 mg film-coated tablets.
Irbesartan Zentiva 75 mg filmsko obložene tablete.
Irbesartan Zentiva can be taken with or without food.
Zdravilo Irbesartan Zentiva lahko jemljete s hrano ali brez nje.
Irbesartan Zentiva is for oral use.
Zdravilo Irbesartan Zentiva je potrebno zaužiti.
Irbesartan Zentiva is used in adult patients
Zdravilo Irbesartan Zentiva uporabljamo pri odraslih bolnikih:
Irbesartan Zentiva slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 zdravilo Irbesartan Zentiva upočasni pešanje delovanja ledvic.
Irbesartan Zentiva with food and drink
Zdravilo Irbesartan Zentiva skupaj s hrano in pijačo
Irbesartan/hydrochlorothiazide combination:
Kombinacija irbesartana in hidroklorotiazida
Irbesartan/Hydrochlorothiazide Teva
Irbesartan/hidroklorotiazid Teva
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets
Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg filmsko obložene tablete
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg filmsko obložene tablete so svetlo rožnate do rožnate, filmsko obložene tablete v obliki kapsul.
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg filmsko obložene tablete irbesartan / hidroklorotiazid
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Zdravilo Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg je namenjeno bolnikom, pri katerih se zvišan krvni tlak med zdravljenjem samo s hidroklorotiazidom ali samo s 150 mg irbesartana ni dovolj znižal.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets
Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg filmsko obložene tablete
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg filmsko obložene tablete so svetlo rožnate do rožnate, filmsko obložene tablete v obliki kapsul.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg filmsko obložene tablete irbesartan / hidroklorotiazid
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg.
Zdravilo Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg je namenjeno bolnikom, pri katerih se krvni tlak med zdravljenjem s 300 mg irbesartana ali z zdravilom Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg ni dovolj znižal.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/hidroklorotiazid Teva 300 mg/25 mg filmsko obložene tablete irbesartan / hidroklorotiazid
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg.
Zdravilo Irbesartan/hidroklorotiazid Teva 300 mg/25 mg je namenjeno bolnikom, pri katerih se krvni tlak med zdravljenjem z zdravilom Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg ni dovolj znižal.
Irbesartan/Hydrochlorothiazide Teva can be taken once daily, with or without food.
Zdravilo Irbesartan/hidroklorotiazid Teva se lahko jemlje enkrat na dan skupaj s hrano ali brez nje.
Irbesartan/Hydrochlorothiazide Teva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Zdravilo Irbesartan/hidroklorotiazid Teva je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
Irbesartan/Hydrochlorothiazide Teva is a ‘generic medicine’.
Irbesartan/Hydrochlorothiazide Teva je „generično zdravilo“.
Irbesartan/Hydrochlorothiazide Teva is available in pack sizes of 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters.
Zdravilo Irbesartan/hidroklorotiazid Teva je na voljo v pakiranjih po 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 in 100 filmsko obloženih tablet v neperforiranem pretisnem omotu; perforirani pretisni omot z enkratnimi odmerki po 50x1 filmsko obložena tableta in koledarsko pakiranje v neperforiranem pretisnem omotu po 28 filmsko obloženih tablet.
Irbesartan/Hydrochlorothiazide Teva is available in pack sizes of 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters.
Zdravilo Irbesartan/hidroklorotiazid Teva je na voljo v pakiranjih po 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 in 100 filmsko obloženih tablet v neperforiranih pretisnih omotih; perforirani pretisni omoti z enkratnimi odmerki po 50x1 filmsko obložena tableta in koledarsko pakiranje v neperforiranem pretisnem omotu po 28 filmsko obloženih tablet.
Irbesartan/Hydrochlorothiazide Teva is for oral use.
Zdravilo Irbesartan/hidroklorotiazid Teva je potrebno zaužiti.
Irbesartan/Hydrochlorothiazide Teva is not recommended for use in children and adolescents because the safety and efficacy have not been established.
Varnost in učinkovitost zdravila Irbesartan/hidroklorotiazid Teva niso bili dokazani, zato uporaba pri otrocih in mladostnikih ni priporočljiva.
Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months.
Irbesartan/hidroklorotiazid: potencialno toksičnost kombinacije irbesartan/hidroklorotiazid so po peroralnem dajanju ocenjevali pri podganah in opicah, v raziskavah, ki so trajale do 6 mesecev.
Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months.
Potencialno toksičnost kombinacije irbesartana in hidroklorotiazida so po peroralnem dajanju ocenjevali pri podganah in opicah v raziskavah, ki so trajale do 6 mesecev.
Irbesartan/Hydrocholorthiazide Teva 300 mg/25 mg film-coated tablets
Irbesartan/hidroklorotiazid Teva 300 mg/25 mg filmsko obložene tablete
Irbesartan: there was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses.
Dokazov o nenormalni sistemski toksičnosti ali toksičnosti za ciljni organ pri klinično primernih odmerkih ni.
IRC Assessment
ocena IRC
IRC Assessment
Ocena neodvisne komisije
IRC evaluated, median follow--up 18.4 months;
ocenjeno s strani IRC, mediano spremljanje 18,4 mesece
IRC evaluated, ORR (CR, Cri, nPR, PR)
ocenjeno s strani IRC, ORR (CR, Cri, nPR, PR)
IRC-assessed PFS (PFS-IRC)
PFS po oceni IRC (PFS-IRC)
IRC-assessed PFS (PFS-IRC)a
PFS po oceni IRC (PFS-IRC)a
IRC-Assessed Primary and Subgroup Analyses of PFS, Months
PFS v analizi primarne skupine in podskupin po oceni IRC, meseci
IRC-assessed progression-free survival (PFS)
Preživetje brez napredovanja bolezni (PFS) po oceni IRC
IRC-Assessed Secondary Outcome
Sekundarni izid po oceni IRC
IRC: Independent Review Committee; PFS: progression-free survival; HR: Hazard Ratio; CI: Confidence Intervals,
IRC: odbor za neodvisni pregled, PFS: preživetje brez napredovanja bolezni, RO: razmerje ogroženosti, IZ: interval zaupanja,
Ire land medac GmbH
Ireland Suomi/Finland medac GmbH
Ireland
+370.5.2780.247
Ireland
880 033 407
Ireland
Galway, IRSKA.
Ireland
Waterford Irska
Ireland and
Galway, IRSKA. in
Ireland medinfoeuceemea@shire.com
Irska email: medinfoeuceemea@shire.com
Ireland.
Cork, Ireland.
Ireland.
Galway, Irska
IRESSA contains lactose
Zdravilo IRESSA vsebuje laktozo.
IRESSA contains the active substance gefitinib which blocks a protein called ‘epidermal growth factor receptor’ (EGFR).
Zdravilo IRESSA vsebuje zdravilno učinkovino gefitinib, ki blokira beljakovino, imenovano "receptor epidermalnega rastnega dejavnika" (EGFR).
IRESSA is a round brown tablet marked with ‘IRESSA 250’ on one side and plain on the other.
Zdravilo IRESSA so okrogle rjave tablete z oznako ‘IRESSA 250‘ na eni strani in brez oznake na drugi.
IRESSA is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (see section 4.4).
Zdravilo IRESSA je indicirano za zdravljenje odraslih bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom z aktivacijskimi mutacijami EGFR-TK (glejte poglavje 4.4).
IRESSA is not indicated in children and adolescents under 18 years.
Uporaba zdravila IRESSA pri otrocih in mladostnikih, starih manj kot 18 let, ni priporočena.
iridocyclitis, eye inflammation, photopsia, eczema eyelids, conjunctival oedema, halo vision, conjunctival follicles, hypoaesthesia eye, meibomianitis, anterior chamber pigmentation, mydriasis, eyelash thickening
iridociklitis, vnetje očesa, fotopsija, ekcem vek, edem veznice, odsev v obliki kolobarjev (halo), veznični folikli, hipoestezija očesa, vnetje Meibomovih žlez, pigmentacija v sprednjem očesnem prekatu, midriaza, odebelitev trepalnic
irinotecan (used to treat cancer)
irinotekan (zdravilo za zdravljenje raka),
Irinotecan belongs to a group of cancer medicines called ‘topoisomerase inhibitors’.
Irinotekan spada v skupino zdravil za zdravljenje raka, imenovanih „zaviralci topoizomeraze“.
Irinotecan dose should be reduced by 15-20% in subsequent cycles.
Odmerek irinotekana je treba v naslednjih ciklusih zmanjšati za 15–20 %.
Irinotecan dose should be reduced by 15-20%.
Odmerek irinotekana je treba zmanjšati za 15 do 20 %.
irinotecan due to an alteration of the metabolism of this medicinal product
irinotekan zaradi spremembe presnove tega zdravila,
Irinotecan, a chemotherapy drug used to treat cancer of the colon and rectum.
irinotekan, kemoterapija, ki se uporablja za zdravljenje raka debelega črevesa in danke,
irinotecan, dasatinib, nilotinib, vinblastine and vincristine (used to treat cancer)
irinotekan, dasatinib, nilotinib, vinblastin in vinkristin (uporabljamo jih za zdravljenje rakavih bolezni)
irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),
irinotekan, etopozid, vinorelbin, ifosfamid (zdravila za zdravljenje raka)
irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),
irinotekan, etopozid, vinorelbin, ifosfamid (zdravila za zdravljenje raka),
Irinotecan: AUC: ↑ 2.1-fold
Irinotekan: AUC: ↑ 2,1-krat
Iris color changes seen with ophthalmic administration of bimatoprost may not be noticeable for several months to years.
Spremembe v barvi šarenice, ki se pojavijo ob očesni uporabi bimatoprosta, so lahko vidne šele čez več mesecev ali let.
Iris disorder,
motnje šarenice,
Iris disorder,
motnje šarenice, midriaza,
Iris inflammation
vnetje šarenice,
IRIS may lead to your condition getting worse, including worsening of brain function.
Zaradi reakcije IRIS se vam bolezen lahko poslabša, kar vključuje tudi poslabšano delovanje možganov.
Iritis
vnetje šarenice
iritis, conjunctival oedema, eyelid pain, visual acuity worsened, trichiasis, iris hyperpigmentation, deepening of eyelid sulcus, eyelid retraction
iritis, edem očesne veznice, bolečina v očesni veki, poslabšana ostrina vida, trihiaza, hiperpigmentacija šarenice, poglobitev sulkusa veke, retrakcija veke
IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and < 1.1 mg/dl in females).
IRMA 2 je dvojno slepa, s placebom kontrolirana raziskava smrtnosti pri 590 bolnikih z diabetesom tipa 2, mikroalbuminurijo (30-300 mg/dan) in normalno ledvično funkcijo (serumski kreatinin pri moških ≤ 1,5 mg/dl, pri ženskah < 1,1 mg/dl).
irolimus and tacrolimus.
koncentracije ciklosporina, sirolimusa in
irolimus-related side
irolimusom povezane
irolimus: used to prevent your body from rejecting a kidney transplant
irolimus: uporablja se za preprečevanje zavrnitve presajene ledvice,
Iron as sucroferric oxyhydroxide
Železo v obliki saharoznega železovega oksihidroksida (sucroferric oxyhydroxide)
IRON CHELATORS
KELATORJI ŽELEZA
Iron deficiencies should be treated prior to starting treatment with Retacrit.
Pomanjkanje železa je treba zdraviti pred začetkom zdravljenja z zdravilom Retacrit.
Iron deficiency anaemia is a common problem in patients with inflammatory bowel disease.
Anemija zaradi pomanjkanja železa je pogosta težava pri bolnikih z vnetno črevesno boleznijo.
iron deficiency anaemia, lymph node pain, lymphadenopathy, neutropenia and anaemia (both occasionally severe), thrombocytopenia
anemija zaradi pomanjkanja železa, bolečine v bezgavkah, limfadenopatija, nevtropenija in anemija (obe občasno hudi), trombocitopenija
Iron evaluation
Določanje železa
Iron overload
preobremenitev z železom;
Iron overload, Weight decreased
preobremenitev z železom, zmanjšana telesna masa
Iron oxide black (E172)
šelak črni železov oksid (E172)
Iron oxide black (E172) Propylene glycol (E1520) Shellac
črni železov osid (E172) propilenglikol (E1520) šelak
Iron oxide black Ammonium hydroxide
črni železov oksid amonijev hidroksid
Iron oxide brown E172 Lactose monohydrate Magnesium stearate Maize starch Microcrystalline cellulose
Rjavi železov oksid E172 Laktoza monohidrat Magnezijev stearat Koruzni škrob
Iron oxide red (E172)
karnauba vosek rdeči železov oksid (E172)
Iron oxide red (E172) Carnauba wax Glycerol mono-oleate
šelak rdeči železov oksid (E172) karnauba vosek glicerilmonooleat
Iron oxide red (E172) Iron oxide black (E172)
mukec rdeči železov oksid (E172) črni železov oksid (E172)
Iron oxide red (E172) Iron oxide black (E172)
rdeči železov oksid (E172) črni železov oksid (E172)
Iron oxide red (E172) Iron oxide black (E172) Iron oxide yellow (E172)
mukec rdeči železov oksid (E172) črni železov oksid (E172) rumeni železov oksid (E172)
Iron oxide red (E172) Iron oxide yellow (E172) Talc
Rdeči železov oksid (E172) Rumeni železov oksid (E172) Smukec
Iron oxide red (E172) Titanium dioxide (E171)
želatina rdeči železov oksid (E172) titanov dioksid (E171)
Iron oxide red and yellow (E172)
Rdeči in rumeni železov oksid (E172)
Iron oxide yellow (E172)
karnauba vosek rumeni železov oksid (E172)
Iron oxide yellow (E172)
mukec rumeni železov oksid (E172)
Iron oxide yellow (E172) Iron oxide red (E172)
karnauba vosek rumeni železov oksid (E172) rdeči železov oksid (E172)
Iron oxide yellow (E172) Iron oxide red (E172)
mukec rumeni železov oksid (E172) rdeči železov oksid (E172)
Iron Oxide Yellow (E172) Polysorbate (E433)
Rumeni železov oksid (E172) Polisorbat (E433)
Iron oxide yellow (E172) Talc
Rumeni železov oksid (E172) Smukec
Iron oxide yellow (E172) Titanium dioxide (E171) Iron oxide red (E172) Lecithin (soya) (E322) Xanthan gum (E415)
delno hidroliziran polivinilalkohol smukec rumeni železov oksid (E172) titanov dioksid (E171) rdeči železov oksid (E172) sojin lecitin (E322) ksantanski gumi (E415)
Iron oxide yellow and red (E 172)
Rumeni in rdeči železov oksid (E 172)
Iron oxide yellow, red and black (E172)
Rumeni, rdeči in črni železov oksid (E172)
Iron oxide, black (E 172) Iron oxide, red (E 172) Titanium dioxide (E 171)
črni železov oksid (E 172) rdeči železov oksid (E 172) titanov dioksid (E 171)
Iron supplementation should be started as soon as possible, even several weeks prior to initiating the autologous predeposit, in order to achieve high iron stores prior to starting Retacrit therapy.
Z dodajanjem železa je treba začeti čim preje, celo več tednov pred začetkom avtolognega odvzema, da bi tako ob začetku terapije z zdravilom Retacrit bolnik imel visoke zaloge železa.
Iron supplementation should be started as soon as possible, even several weeks prior to initiating the autologous predeposit, in order to achieve high iron stores prior to starting Silapo therapy.
Z dodajanjem železa je treba začeti čim preje, celo več tednov pred začetkom avtolognega odvzema, da bi tako ob začetku terapije z zdravilom Silapo bolnik imel visoke zaloge železa.
iron supplementation, e.g.
dodajanje železa, npr.
Iron supplements
Železovi dodatki
Iron supplements and other blood stimulants may increase the effectiveness of Abseamed.
Dodatki železa in druga sredstva za spodbujanje tvorbe krvi lahko povečajo učinkovitost zdravila Abseamed.
Iron supplements and other blood stimulants may increase the effectiveness of Binocrit.
Dodatki železa in druga sredstva za spodbujanje tvorbe krvi lahko povečajo učinkovitost zdravila Binocrit.
Iron supplements and other blood stimulants may increase the effectiveness of Epoetin alfa HEXAL.
Dodatki železa in druga sredstva za spodbujanje tvorbe krvi lahko povečajo učinkovitost zdravila Epoetin alfa HEXAL.
Iron supplements were also given to all the patients to help treat anaemia.
Vse bolnice so prejemale tudi dodatke železa proti anemiji.
Irradiation by the emitted beta particles from 90Y occurs in a radius of 5 mm around the isotope.
Obsevanje z beta delci, ki jih oddaja 90Y, sega v radiju 5 mm okrog izotopa.
Irregular bleeding and/or spotting was reported in the CE 0.45 mg/ bazedoxifene 20 mg group by 6% of women during the first 3 months of treatment and by 5% of women during months 10 to 12.
V skupini s kombinacijo 0,45 mg CE/20 mg bazedoksifena je o neredni krvavitvi in/ali krvavkastem izcedku poročalo 6 % žensk v prvih 3 mesecih zdravljenja in 5 % žensk med 10. in 12. mesecem.
Irregular bleeding and/or spotting was reported in the CE 0.45 mg/ bazedoxifene 20 mg group by 7% of women during the first 3 months of treatment and by 3% of women during months 10 to 12.
V skupini s kombinacijo 0,45 mg CE/20 mg bazedoksifena je o neredni krvavitvi in/ali krvavkastem izcedku poročalo 7 % žensk v prvih 3 mesecih zdravljenja in 3 % žensk med 10. in 12. mesecem.
irregular heart beat
nepravilen srčni utrip
Irregular heart beat
nepravilen srčni utrip,
Irregular heart beat
neredno bitje srca
irregular heart beat
neredno bitje srca,
irregular heart beat (atrial fibrillation), heart attack
nereden srčni utrip (atrijska fibrilacija), srčni infarkt
irregular heart beat blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
nepravilen srčni utrip krvni strdki v venah, največkrat v venah nog (simptomi so oteklina, bolečina in rdečina noge), lahko po žilah pridejo v pljuča in povzročijo bolečine v prsih in težko dihanje.
irregular heart beat liver disorder
nepravilen srčni utrip bolezen jeter
Irregular heart beat or heart rhythm disturbances
nereden srčni utrip ali motnje srčnega ritma
irregular heart beat redness of the face (flush).
neredno bitje srca rdečica obraza (vročinski obliv)
Irregular heart beat;
neredno bitje srca,
irregular heart beats
nepravilni srčni utripi
Irregular heart beats.
Neenakomeren srčni utrip.
Irregular heart rate, increased blood pressure, bleeding, fast heart rate
motnje srčnega ritma, zvišan krvni tlak, krvavitev, hitro bitje srca,
Irregular heart rhythm
neenakomeren srčni utrip;
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving Aclasta for the treatment of postmenopausal osteoporosis.
Pri bolnicah, ki so prejemale zdravilo Aclasta zaradi postmenopavzalne osteoporoze, so poročali o nepravilnem bitja srca (atrijski fibrilaciji).
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis.
Pri bolnicah, ki so dobivale zoledronsko kislino zaradi postmenopavzalne osteoporoze, so opažali neredno bitje srca (atrijsko fibrilacijo).
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for the treatment of postmenopausal osteoporosis.
Pri bolnicah, ki so prejemale zdravilo Zoledronska kislina Hospira zaradi postmenopavzalne osteoporoze, so poročali o nepravilnem bitja srca (atrijski fibrilaciji).
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving Zoledronic acid Teva Pharma for the treatment of postmenopausal osteoporosis.
Pri bolnicah, ki so prejemale zdravilo Zoledronska kislina Teva Pharma zaradi postmenopavzalne osteoporoze, so poročali o nepravilnem bitja srca (atrijski fibrilaciji).
Irregular heartbeat
Nepravilen srčni utrip.
irregular heartbeat
nereden srčni utrip,
irregular heartbeat
neredno bitje srca
irregular heartbeat
neredno bitje srca,
irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)
neenakomerni srčni utrip in palpitacije (aritmije), bolečina v prsih in srčni napad (infarkt),
irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)
neobičajno bitje srca in palpitacije (aritmija), bolečine v prsnem košu in srčni napad (infarkt)
irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)
nereden srčni utrip in palpitacije (aritmije), bolečino v prsnem košu in srčni napad (infarkt),
irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction),
nereden srčni utrip in palpitacije (aritmije), bolečino v prsnem košu in srčni napad (infarkt),
irregular heartbeat, including an abnormally slow or fast beating of the heart
nepravilno bitje srca, vključno z nenormalno počasnim ali hitrim bitjem srca
Irregular menstrual cycle, vaginal bleeding, dryness of the female vulva and vagina
neredna menstruacija, krvavitev iz nožnice, suhost vulve in nožnice;
Irregular menstruation (NB), Vaginal haemorrhage (NB), Erectile dysfunction (NB,N)a, Vulvovaginal dryness (NB)
neredna menstruacija (NB), vaginalna krvavitev (NB), erektilna disfunkcija (NB,N)a, suhost vulve/nožnice (NB)
irregular or abnormal heart beat
motnje srčnega ritma